Viridian Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Denver CO United States (2007)

Organization Overview

First Clinical Trial
2021
NCT05176639
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Viridian Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

lapatinib (tykerb) (1 trial)

vrdn-001 (2 trials)

Drugs in Phase 2 Trials (3)

Key: Viridian Therapeutics (0) Acquired (3)

cobomarsen (2 trials)

remlarsen (2 trials)

vorinostat (zolinza) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Viridian Therapeutics (0) Acquired (2)

mrg-106 (1 trial)

mrg-110 (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 7